Carboplatin Injection is supplied as a sterile, aqueous solution available in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL or 600 mg/60 mL multi-dose vials containing 10 mg/mL of carboplatin for administration by intravenous infusion.
Carboplatin Injection is indicated for the following:
Initial Treatment of Advanced Ovarian Carcinoma
Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES).
There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.
Secondary Treatment of Advanced Ovarian Carcinoma
Carboplatin Injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Media Articles Related to Carboplatin
Counting tumor-attacking immune cells to predict ovarian cancer survival
Source: Immune System / Vaccines News From Medical News Today [2013.12.06]
One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.
New Test May Help Predict Survival From Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2013.12.05]
Title: New Test May Help Predict Survival From Ovarian Cancer
Category: Health News
Created: 12/4/2013 2:36:00 PM
Last Editorial Review: 12/5/2013 12:00:00 AM
Source: MedicineNet Cancer Causes Specialty [2013.09.24]
Title: Ovarian Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/24/2013 12:00:00 AM
New Hope for Early Detection of Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2013.08.26]
Title: New Hope for Early Detection of Ovarian Cancer
Category: Health News
Created: 8/26/2013 9:35:00 AM
Last Editorial Review: 8/26/2013 12:00:00 AM
Ovarian Cancer Pictures Slideshow: Symptoms, Stages, Treatments and Risks
Source: MedicineNet Cancer Causes Specialty [2013.07.24]
Title: Ovarian Cancer Pictures Slideshow: Symptoms, Stages, Treatments and Risks
Created: 11/11/2010 6:08:00 PM
Last Editorial Review: 7/24/2013 12:00:00 AM
Published Studies Related to Carboplatin
BEAM: a randomized phase II study evaluating the activity of bevacizumab in
combination with carboplatin plus paclitaxel in patients with previously
untreated advanced melanoma. 
metastatic melanoma... CONCLUSION: The study did not meet the primary objective of statistically
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. [2011.09.17]
BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended for patients older than 70 years. We compared a carboplatin and paclitaxel doublet chemotherapy regimen with monotherapy in elderly patients with advanced NSCLC... INTERPRETATION: Despite increased toxic effects, platinum-based doublet chemotherapy was associated with survival benefits compared with vinorelbine or gemcitabine monotherapy in elderly patients with NSCLC. We feel that the current treatment paradigm for these patients should be reconsidered. FUNDING: Intergroupe Francophone de Cancerologie Thoracique, Institut National du Cancer. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. [2011.08.10]
PURPOSE: Cancer and Leukemia Group B conducted a randomized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent thoracic radiation therapy (TRT)... CONCLUSION: The combination of pemetrexed, carboplatin, and TRT met the prespecified criteria for further evaluation. This regimen should be studied further in patients with locally advanced unresectable nonsquamous NSCLC.
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. [2011.08.01]
PURPOSE: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone... CONCLUSION: The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. [2011.08]
OBJECTIVE: To describe and analyze observed hypersensitivity reactions (HSR) from the randomized, multicenter phase III CALYPSO trial that evaluated the efficacy and safety of the combination of carboplatin and pegylated liposomal doxorubicin (CD) compared with standard carboplatin-paclitaxel (CP) in patients with platinum-sensitive relapsed ovarian cancer (ROC)... CONCLUSIONS: Use of PLD with carboplatin instead of paclitaxel and older age were the only 2 factors predicting a low rate of HSRs in patients with ROC. CD has previously demonstrated superior progression-free survival and therapeutic index than CP. Taken together these data support the use of CD as a safe and effective therapeutic option for platinum-sensitive ROC. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Carboplatin
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy [Recruiting]
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab
plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival
time without disease progression in the first-line treatment of patients with advanced stage
non-small cell lung cancer.
Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC [Recruiting]
To see the efficacy of using chemotherapies alternatively (carboplatin and gemcitabine alternating with carboplatin and taxol) for pts with stage IIIB (nonresectable and stage IV NSCLC.
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Followed by Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung [Completed]
Patients enrolled on this study will have been diagnosed with non-small cell lung cancer
which cannot be removed by an operation. The standard treatment for this disease is a
combination of chemotherapy and radiation therapy; however, the best way to combine these
treatments is not known. This study will examine if the combination of chemotherapy and
radiotherapy has an increased effect on slowing tumor growth with the addition of a drug
In this study, chemotherapy will be given initially (induction therapy) to try to control the
spread of the cancer. Then radiation and chemotherapy will be given together. Receiving
chemotherapy at the same time as radiation treatments can enhance the effect of the
radiation. In this study, patients will receive a drug called ZD1839. In laboratory tests on
cancer cells, ZD1839 has shown an additive effect when used in combination with radiation.
ZD1839 has also been shown to slow or stop growth in tumors.
The purpose of this study is to determine the side effects and effectiveness of using ZD1839
when used with radiation in this treatment regimen (induction chemotherapy followed by
combination chemotherapy, ZD1839, and radiation therapy).
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer [Completed]
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small
cell lung carcinoma.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where
it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving
these drugs in non small cell lung carcinoma.
Phase II Trial of Gemcitabine and Carboplatin Followed by Paclitaxel and Carboplatin With Radiation for Stage IIIA/IIIB NSCLC. [Active, not recruiting]
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment starts with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation includes using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy. Response rate will be determined following the chemotherapy with gemcitabine and carboplatin and evaluated again after the chemoradiation. Treatment toxicities will also be assessed.
Reports of Suspected Carboplatin Side Effects
Febrile Neutropenia (206),
Pyrexia (141), more >>